Results 131 to 140 of about 15,701 (194)

Evaluation of the efficacy of empagliflozin in patients with preserved left ventricular ejection fraction undergoing transcatheter aortic valve implantation for aortic stenosis: protocol for a randomised, open-label, controlled study. [PDF]

BMJ Open
Okita S, Kitahara H, Shoji M, Sugawara T, Miyakoda K, Yaginuma H, Yamamoto H, Kanda T, Kinoshita M, Sasaki H, Suzuki-Eguchi N, Takaoka H, Matsuura K, Ozawa Y, Hanaoka H, Matsumiya G, Kobayashi Y.   +16 more
europepmc   +1 more source

Empagliflozin modulates microRNA expression in human primary cardiomyocytes under CoCl₂-induced hypoxia. [PDF]

Int J Cardiol Cardiovasc Risk Prev
Samec M, Baranova I, Dibdiakova K, Samec I, Samos M, Pec MJ, Pecova R, Pec M.   +7 more
europepmc   +1 more source

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications. [PDF]

Drugs Context
Manunta M, Bruno GM, Ferrantelli A, Ramirez RF, Nardi F.   +4 more
europepmc   +1 more source

Acute vascular redox modulation by SGLT2 inhibition in non-diabetic patients. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Lukenda KC, Gasparovic AC, Milic M, Radovani B, Vuckovic F, Jakab J, Vucic D, Kovacevic A, Gudelj I.   +8 more
europepmc   +1 more source

Effects of empagliflozin on right ventricular free-wall strain in patients with heart failure and reduced ejection fraction: results from the Empire HF Trial. [PDF]

ESC Heart Fail
Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videbæk L, Poulsen MK, Tuxen CD, Borlaug BA, Möller S, Gustafsson F, Køber L, Schou M, Møller JE.   +13 more
europepmc   +1 more source

Sodium-Glucose Cotransporter 2 Inhibitors: Does One Size Fit All? [PDF]

Clin Cardiol
Morariu PC, Godun MM, Marcu MTD, Floria M.   +3 more
europepmc   +1 more source

Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database. [PDF]

Front Med (Lausanne)
Yin M, Tan H, Xie S, Kuang Y, Wu Q, Ma J, Guo C.   +6 more
europepmc   +1 more source

Adipose-Derived Proinflammatory Visfatin Promotes Vascular Calcification via TLR4 and is Suppressed by Empagliflozin. [PDF]

Inflammation
Zhang Y, Zhao Y, Luo Y, Wang L, Liao J, Lu H, Zhang X, Ji X.   +7 more
europepmc   +1 more source

Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status. [PDF]

Kidney Int Rep
Correa-Rotter R, Rossing P, Canziani ME, Caramori ML, Cherney D, Cronin L, Hugo C, Ji B, Meyerhoff J, Nangaku M, Silva A, Urbach D, Shah SV, de Zeeuw D, Tuttle KR.   +14 more
europepmc   +1 more source

Comparison of effectiveness and safety of bexagliflozin and other sodium-glucose cotransporter 2 inhibitors for type 2 diabetes mellitus in adults: systematic review and network meta-analysis of randomized controlled trials. [PDF]

Front Endocrinol (Lausanne)
Gao S, Zhang F, Xie X, Fan L.
europepmc   +1 more source